Cost effectiveness of palivizumab in children with congenital heart disease in Germany

Journal of Medical Economics

Volumn 12, Issue 4, 2009, Pages 301-308

  Nuijten, Mark ^a,b   Lebmeier, Maximilian ^c   Wittenberg, Wolfgang ^d  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b Ars Accessus Medica   (Netherlands)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Cost effectiveness; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; ASTHMA; CHEMOPROPHYLAXIS; CONGENITAL HEART DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; EXPERIMENTAL MODEL; FOLLOW UP; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; INFECTION PREVENTION; INTENSIVE CARE UNIT; LIFE EXPECTANCY; MORBIDITY; MORTALITY; PRODUCTIVITY; QUALITY OF LIFE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SENSITIVITY ANALYSIS; VIRUS INFECTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION TREES; GERMANY; HEALTH SERVICES; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 72749119455     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903347172     Document Type: Article

References (34)

1. Simoes E. Respiratory syncytial virus infection. Lancet 1999;354:847-852.
2. Hall C. Respiratory syncytial virus. In: Feigin R, Cherry J, eds. Infectious Diseases. Philadelphia: W.B. Saunders, 1998.
3. Berner R, Schwoerer F, Schumacher RF, et al. Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur J Pediatr 2001;160:541-547.
4. Liese JG, Grill E, Fischer B, et al. Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:230-236.
5. Canfield S, Simoes E. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. Pediatric Ann 1999;28:507-514.
6. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212-219.
7. Navas L, Wang E, De Carvalho V, Robinson J. Pediatric Investigators Collaborative Network on Infections in Canada: improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr 1992;121:348-354.
8. Moler FW, Khan AS, Meliones JN, et al. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992;20:1406-1413.
9. Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease; postoperative course and outcome. Crit Care Med 1999;27:1974-1981.
10. Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-438.
11. Malhotra A, Krilov L. Influenza and respiratory syncytial virus. Update on infection, management and prevention. Pediatr Clin North Am 2000;47:353-372.
12. Bont L, Aalderen WM, Kimpen JL. Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr Respir Rev 2000;1:221-227.
13. European Medicines Agency. http://www.emea.eu.int/humandocs/Humans/EPAR/ synagis/Synagis.htm.
14. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-540.
15. Palivizumab prescribing information.
16. Nuijten, MJC. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998;14:433-445.
17. Nuijten MJ. The selection of data sources for use in modelling studies. Pharmacoeconomics 1998;13:305-316.
18. Brecht JG, Jenke A, Kohler ME, et al. Recommendations of the German Society of Clinical Pharmacology and Therapy for implementing and evaluating pharmaco-economic studies. Med Klin (Munich) 1995;90:541-556.
19. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). German recommendations on health economic evaluation studies. Revised version of the Hannover Consensus, 1995.
20. Simoes EA, Sondheimer HM, Top FH Jr, et al.; Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133:492-499.
21. Rodriguez WJ, Parrott RH. Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants. Infect Dis Clin North Am 1987;1:425-439.
22. Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: A UK analysis. Pharmacoeconomics 2007;25:55-71.
23. Statistisches bundesamt Deutschland. www.destatis.de.
24. Wren C, O'Sullivan JJ. Survival with congenital heart disease and need for follow up in adult life. Heart 2001;85:438-443. (Pubitemid 32973534)
25. Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalization for RSV infection. Arch Dis Child 2004;89:673-678.
26. Roeckl-Wiedmann I, Liese JG, Grill E, et al. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003:162;237-244.
27. 3M Medica - Health Information Systems. DRG online grouper http://www.grdrg.de/GrouperCGI/OnlineGrouper.exe.
28. Graf Von Der Schulenburg JM, Greiner W, Molitor S, et al. Cost of asthma therapy in relation to severity. An empirical study. Med Klin (Munich) 1996;91:670-676.
29. Organisation for Economic Co-operation and Development (OECD). OECD Employment Outlook 2004. www.oecd.org.
30. Laufer F. Thresholds in cost-effectiveness analysis - more of the story. Value Health 2005;8:886-887.
31. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-1611.
32. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics 2004;114:1612-1619.
33. Lofland JH, O'Connor JP, Chatterton ML, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000;22:1357-1369.
34. Resch B, Gusenleitner W, Nuijten MJC, et al. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008;30:749-760.